IFNG and neoplasm: Moreover, co-immunisation with the adjuvant CpG promotes enhanced antigen specific IFN-γ and IL-4 T cell responses, induces a Th1 response, characterised by a higher ratio of IgG2a /IgG1 antibodies and delays tumour growth in vivo.